Literature DB >> 7584096

A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.

R Vile1, N Miller, Y Chernajovsky, I Hart.   

Abstract

To target therapeutic genes specifically to melanoma cells, we have constructed recombinant retroviruses where transcriptional control of the murine interleukin-2 (mIL-2) or herpes simplex virus thymidine kinase (HSVtk) genes is provided by the 5' promoter region of the murine tyrosinase gene. Tissue-specific expression of these genes is observed both at the mRNA and protein levels in the B16 melanoma line compared with NIH3T3 fibroblasts. Thus, B16 cells infected with one such retrovirus containing the HSVtk gene exhibited a > 90% reduction in colony-forming efficiency after exposure to 1 microgram/ml ganciclovir, relative to controls, whereas similarly infected NIH3T3 cells showed < 10% reduction in colony-forming efficiency under comparable conditions. The degree of preservation of tissue-specific expression from the internal tyrosinase promoter depended upon the exact molecular design of the vector, possibly as a consequence of the interference between closely juxtaposed promoters within the provirus. Our results show that retroviral vectors can be prepared with the capacity to regulate expression of inserted genes specifically in a particular cell type and may be useful for developing efficient, targeted vectors for the in vivo delivery of genetic therapies for malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584096

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

2.  Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Authors:  R M Diaz; T Eisen; I R Hart; R G Vile
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 3.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Targeted vectors for gene therapy of cancer and retroviral infections.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

5.  Transcriptional targeting of herpes simplex virus for cell-specific replication.

Authors:  S Miyatake; A Iyer; R L Martuza; S D Rabkin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Pantropic retroviruses as a transduction tool for sea urchin embryos.

Authors:  Amanda B Core; Arlene E Reyna; Evan A Conaway; Cynthia A Bradham
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

7.  Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy.

Authors:  P M Cannon; N Kim; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.

Authors:  S Chaurasiya; P Hew; P Crosley; D Sharon; K Potts; K Agopsowicz; M Long; C Shi; M M Hitt
Journal:  Cancer Gene Ther       Date:  2016-05-06       Impact factor: 5.987

9.  Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences.

Authors:  U Jäger; Y Zhao; C D Porter
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 10.  Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

Authors:  W Walther; U Stein
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.